Jump to content

User:WikiGynnQueens/sandbox

From Wikipedia, the free encyclopedia

Management

[edit]

Treatment of AMD varies depending on the category of the disease at the time of diagnosis. In general, treatment is aimed at slowing down the progression of AMD.[1] As of 2018, there are no treatments to reverse the effects of AMD[1]. Early-stage and intermediate-stage AMD is managed by modifying known risk factors such as smoking and atherosclerosis and making dietary modifications.[1] For intermediate-stage AMD, management also includes antioxidant and mineral supplementation.[1][2][3] Advanced-stage AMD is managed based on the presence of choroidal neovascularization (CNV): dry AMD (no CNV present) or wet AMD (CNV present).[1] No effective treatments exist for dry AMD.[1] The CNV present in wet AMD is managed with vascular endothelial growth factor (VEGF) inhibitors.[1][4][5]


Dry AMD

[edit]

No medical or surgical treatment is available for this condition.

Wet AMD

[edit]

Ranibizumab and aflibercept are approved VEGF inhibitors for the treatment of CNV in wet AMD.[4] Bevacizumab is another VEGF inhibitor that has been shown to have similar efficacy and safety as the previous two drugs, however, is not currently indicated for AMD.[5] AMD can also be treated with laser coagulation therapy.[6]

  1. ^ a b c d e f g Bishop P. Age-related macular degeneration. BMJ Best Practice. 2018.
  2. ^ Evans, Jennifer R; Lawrenson, John G (2017-07-30). "Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd000253.pub4. ISSN 1465-1858.
  3. ^ Lawrenson, John G; Evans, Jennifer R (2015-04-09). "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010015.pub3. ISSN 1465-1858.
  4. ^ a b Sarwar, Salman; Clearfield, Elizabeth; Soliman, Mohamed Kamel; Sadiq, Mohammad Ali; Baldwin, Andrew J; Hanout, Mostafa; Agarwal, Aniruddha; Sepah, Yasir J; Do, Diana V (2016-02-08). "Aflibercept for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011346.pub2. ISSN 1465-1858. PMC 5030844. PMID 26857947.{{cite journal}}: CS1 maint: PMC format (link)
  5. ^ a b Lawrenson, John G; Evans, Jennifer R (2015-04-09). "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010015.pub3. ISSN 1465-1858.
  6. ^ Virgili, Gianni; Bini, Alessandro (2007-07-18). "Laser photocoagulation for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004763.pub2. ISSN 1465-1858.

Comments

[edit]

Thanks for all of these suggestions. I think you have done a great job organizing this info and finding high quality sources in your ref list. A few notes:

  • When citing references, please place them immediately after the punctuation like this.1
  • Remember that as per WP:MEDRS we cannot add in RCTs. If you have a reference that has reviewed this RCT, you can change the sentence to: Bevacizumab and ranibizumab have/appear to have/may have (depending on the strength of the evidence) , and there are no side effects .... (once again, the use no "no/may not be/weak evidence suggests that depends on the strength of evidence you are presenting which will come from the secondary source). Cochrane reviews always state the strength of evidence.
  • See if you can add Wikilinks to a few med terms- IV could use one, unless already linked earlier in the article
  • Can you expand this sentence a little "light of a certain wavelength is then applied to the abnormal blood vessels" to explain it to readers who are not familiar with this field?
  • I see you also have a second sentence explaining the results of a RCT. All your references look like great high quality secondary sources. Please see above comment for both instances where it appears you are citing a primary study. If you have any questions please do not hesitate to let me know.

Thanks again for helping to improve the article. JenOttawa (talk) 16:17, 6 November 2018 (UTC)

You did a nice job here improving the text. Do you have a reference indicating that there are no tx options for dry AMD? JenOttawa (talk) 16:17, 6 November 2018 (UTC)